ASX RELEASE
11 November 2026

First Sale of iTrack™ Advance in South Korea

Highlights

- **First commercial sale of iTrack™ Advance made in South Korea during the first week of November 2026.**
- **Follows regulatory clearance from the Ministry of Food and Drug Safety (MFDS) in mid-2025 and approval of device pricing under South Korea's National Health Insurance system in September 2026.**
- **Sales in South Korea, through a distribution partner, are expected to add to revenue growth in FY27.**

Nova Eye Medical Limited (ASX: EYE) (**Nova Eye** or **the Company**), a medical technology company committed to advanced ophthalmic treatment technologies and devices, is pleased to announce that it has made its first commercial sale of iTrack™ Advance in South Korea during the first week of November 2026.

Following regulatory clearance of iTrack™ Advance from the Ministry of Food and Drug Safety (**MFDS**) in South Korea in mid-2025, approval of device pricing arrangements was received during September 2026 from the Health Insurance Review and Assessment Service (**HIRA**) under South Korea's National Health Insurance system. This cleared the way for the launch of iTrack™ Advance in the attractive South Korean market.

South Korea Market Opportunity

South Korea is expected to be a strong market for iTrack™ *Advance* for the following reasons:

- A relatively high level of GDP and economic development, with advanced health care facilities and trained ophthalmologists.
- Meaningful adoption of interventional glaucoma, led by glaucoma specialists.
- National Health Insurance Service data indicate that South Korean surgeons performed approximately 690,000 cataract surgeries in 2025, which in turn suggests there may be more than 100,000[1] patients each year presenting for cataract surgery who also have glaucoma.
- iTrack™ Advance can also be performed as a standalone glaucoma procedure. This adds to the addressable market. HIRA data show that approximately 1.2 million people were treated for glaucoma (both pharmaceutical and surgical treatment) in South Korea in 2023.

Sales in South Korea will be made through an established and experienced ophthalmic distribution partner and are expected to add to the Company's revenue growth in FY27.

-ENDS-

1. Marketscope Glaucoma Surgical Devices Report August 2026: approximately 15% of patients who present for cataract surgery have concurrent glaucoma.

Authorised for lodgement by the Board of Directors of Nova Eye Medical Limited.

For more information please contact:

Company
Tom Spurling
Managing Director
+61 417 818 658
tspurling@nova-eye.com

Investors
Mark Flynn
Investor Relations
+61 416 068 733
mflynn@nova-eye.com

ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons globally, these technologies include iTrack™ Advance, a minimally invasive consumable glaucoma surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The Molteno3® glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe glaucoma. It also offers the benefit of a simplified and faster surgical procedure. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by a global network of distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

For additional information about Nova Eye Medical and its technologies, please visit: www.nova-eye.com